본문 바로가기
KERD
논문KCI 등재

SIRT1 ISGylation accelerates tumor progression by unleashing SIRT1 from the inactive state to promote its deacetylase activity

송현규|허강민|장규윤|Kim Min-Jung|Lee Haeseung|Cho Sang Woo|정명자|Kim You-Sun|Lee Cheol-Jung|Chung Chaeuk|Kang Ji An|Kim Yoon Jung|Moon Hye Won|Lee Seonjeong|Yoo Yoon Sun|Han Hye Gyeong|Choi Cheol Yong|Jeon Young Joo
생화학분자생물학회 (Korean Society Of Biochemistry And Molecular Biology)|2024.12|Experimental and Molecular Medicine|제56권 |pp. 656-673|DOI 10.1038/s12276-024-01194-2

2

조회

0

다운로드

0

인용

0

참고문헌

주제분류생화학

초록

ISG15 is an interferon-stimulated ubiquitin-like protein (UBL) with multifaceted roles as a posttranslational modifier in ISG15 conjugation (ISGylation). However, the mechanistic consequences of ISGylation in cancer have not been fully elucidated, largely due to a lack of knowledge on the ISG15 target repertoire. Here, we identified SIRT1, a nicotinamide adenine dinucleotide (NAD+)-dependent protein deacetylase, as a new target for ISGylation. SIRT1 ISGylation impairs the association of SIRT1 with its negative regulator, deleted in breast cancer 1 (DBC1), which unleashes SIRT1 from its inactive state and leads to an increase in its deacetylase activity. Importantly, SIRT1 ISGylation promoted lung cancer progression and limited lung cancer cell sensitivity to DNA damage-based therapeutics in vivo and in vitro models. The levels of ISG15 mRNA and protein were significantly higher in lung cancer tissues than in adjacent normal tissues. Accordingly, elevated expression of SIRT1 and ISG15 was associated with poor prognosis in lung cancer patients, a finding that could be translated for lung cancer patient stratification and disease outcome evaluation. Taken together, our findings provide a mechanistic understanding of the regulatory effect of SIRT1 ISGylation on tumor progression and therapeutic efficacy in lung cancer.

Abstract

ISG15 is an interferon-stimulated ubiquitin-like protein (UBL) with multifaceted roles as a posttranslational modifier in ISG15 conjugation (ISGylation). However, the mechanistic consequences of ISGylation in cancer have not been fully elucidated, largely due to a lack of knowledge on the ISG15 target repertoire. Here, we identified SIRT1, a nicotinamide adenine dinucleotide (NAD+)-dependent protein deacetylase, as a new target for ISGylation. SIRT1 ISGylation impairs the association of SIRT1 with its negative regulator, deleted in breast cancer 1 (DBC1), which unleashes SIRT1 from its inactive state and leads to an increase in its deacetylase activity. Importantly, SIRT1 ISGylation promoted lung cancer progression and limited lung cancer cell sensitivity to DNA damage-based therapeutics in vivo and in vitro models. The levels of ISG15 mRNA and protein were significantly higher in lung cancer tissues than in adjacent normal tissues. Accordingly, elevated expression of SIRT1 and ISG15 was associated with poor prognosis in lung cancer patients, a finding that could be translated for lung cancer patient stratification and disease outcome evaluation. Taken together, our findings provide a mechanistic understanding of the regulatory effect of SIRT1 ISGylation on tumor progression and therapeutic efficacy in lung cancer.

참고문헌 (100)

  1. Haas, A. L., "Interferon induces a 15-kilodalton protein exhibiting marked homology to ubiquitin", J. Biol. Chem, 262, pp.11315~11323 (1987)
  2. Han, H. G., "ISG15 in cancer : beyond ubiquitin-like protein", Cancer Lett, 438, pp.52~62 (2018)
  3. Desai, S. D., "ISG15 disrupts cytoskeletal architecture and promotes motility in human breast cancer cells", Exp. Biol. Med, 237, pp.38~49 (2012)
  4. Yang, H., "Hrd1-mediated BLIMP-1 ubiquitination promotes dendritic cell MHCII expression for CD4 T cell priming during inflammation", J. Exp. Med, 211, pp.2467~2479 (2014)
  5. Hermann, M. -R., "Integrins synergise to induce expression of the MRTF A–SRF target gene ISG15 for promoting cancer cell invasion", J. Cell Sci, 129, pp.1391~1403 (2016)
  6. Sainz, B., "ISG15 is a critical microenvironmental factor for pancreatic cancer stem cells", Cancer Res, 74, pp.7309~7320 (2014)
  7. Sun, J., "Loss of TRIM29 suppresses cancer stem cell-like characteristics of PDACs via accelerating ISG15 degradation", Oncogene, 39, pp.546~559 (2019)
  8. Fan, J. -B., "Type I interferon regulates a coordinated gene network to enhance cytotoxic T cell–mediated tumor killing", Cancer Discov, 10, pp.382~393 (2020)
  9. Bogunovic, D., "Mycobacterial disease and impaired IFN-γ immunity in humans with inherited ISG15 deficiency", Science, 337, pp.1684~1688 (2012)
  10. Okumura, A., "ISG15 inhibits Ebola VP40 VLP budding in an L-domain-dependent manner by blocking Nedd4 ligase activity", Proc. Natl. Acad. Sci. USA, 105, pp.3974~3979 (2008)
  11. Swaim, C. D., "Extracellular ISG15 signals cytokine secretion through the LFA-1 integrin receptor", Mol. Cell, 68, pp.581~590 (2017)
  12. Yuan, W., "Influenza B virus NS1 protein inhibits conjugation of the interferon(IFN)-induced ubiquitin-like ISG15 protein", Embo J, 20, pp.362~371 (2001)
  13. Zhao, C., "The UbcH8 ubiquitin E2 enzyme is also the E2 enzyme for ISG15, an IFN-alpha", beta-induced ubiquitin-like protein, 2004, pp.101, 7578~7582
  14. Kim, K. I., "Interferon-inducible ubiquitin E2, Ubc8, is a conjugating enzyme for protein ISGylation", Mol. Cell. Biol, 24, pp.9592~9600 (2004)
  15. Okumura, F., "ISG15 modification of the eIF4E cognate 4EHP enhances cap structure-binding activity of 4EHP", Genes Dev, 21, pp.255~260 (2007)
  16. Tan, N. G., "Human homologue of Ariadne promotes the ubiquitylation of translation initiation factor 4E homologous protein, 4EHP", FEBS Lett, 554, pp.501~504 (2003)
  17. Zou, W., "The interferon-inducible ubiquitin-protein isopeptide ligase(E3)EFP also functions as an ISG15 E3 ligase", J. Biol. Chem, 281, pp.3989~3994 (2006)
  18. Dastur, A., "Herc5, an interferon-induced HECT E3 enzyme, is required for conjugation of ISG15 in human cells", J. Biol. Chem, 281, pp.4334~4338 (2006)
  19. Wong, J. J., "HERC5 is an IFN-induced HECT-type E3 protein ligase that mediates type I IFN-induced ISGylation of protein targets", Proc. Natl. Acad. Sci. USA, 103, pp.10735~10740 (2006)
  20. Ketscher, L., "mHERC6 is the essential ISG15 E3 ligase in the murine system", Biochem. Biophys. Res. Commun, 417, pp.135~140 (2012)
  21. Malakhov, M. P., "UBP43(USP18)specifically removes ISG15 from conjugated proteins", J. Biol. Chem, 277, pp.9976~9981 (2002)
  22. Basters, A., "Structural basis of the specificity of USP18 toward ISG15", Nat. Struct. Mol. Biol, 24, pp.270~278 (2017)
  23. Jeon, Y. J., "Chemosensitivity is controlled by p63 modification with ubiquitin-like protein ISG15", J. Clin. Invest, 122, pp.2622~2636 (2012)
  24. Ochi, K., "Prediction of response to neoadjuvant chemotherapy for osteo sarcoma by gene-expression profiles", Int. J. Oncol, 24, pp.647~655 (2004)
  25. Park, J. M., "Modification of PCNA by ISG15 plays a crucial role in termination of error-prone translesion DNA synthesis", Mol. Cell, 54, pp.626~638 (2014)
  26. Pitha-Rowe, I., "Retinoid target genes in acute promyelocytic leukemia", Leukemia, 17, pp.1723~1730 (2003)
  27. Kang, J. A., "The diverse repertoire of ISG15 : More intricate than initially thought", Exp. Mol. Med, 54, pp.1779~1792 (2022)
  28. Giannakopoulos,N.V., "Proteomicidentification of proteins conjugated to ISG15in mouse and human cells", Biochem. Biophys. Res. Commun, 336, pp.496~506 (2005)
  29. Zhao, C., "Human ISG15conjugation targets both IFN-induced and constitutively expressed proteins functioning in diverse cellular pathways", Proc. Natl. Acad. Sci. USA, 102, pp.10200~10205 (2005)
  30. Malakhov, M. P., "High-throughput immunoblotting : ubiquitin-like protein ISG15 modifies key regulators of signal transduction", J. Biol. Chem, 278, pp.16608~16613 (2003)
  31. Yan, S., "IRF3 reduces adipose thermogenesis via ISG15-mediated repro gramming of glycolysis", J. Clin. Invest, 131, pp.e144888~ (2021)
  32. Zhang, Y., "The in vivo ISGylome links ISG15 to metabolic pathways and autophagy upon Listeria monocytogenes infection", Nat. Commun, 10, pp.1~15 (2019)
  33. Park, J. H., "Positive feedback regulation of p53 transactivity by DNA damage-induced ISG15 modification", Nat. Commun, 7, pp.12513~ (2016)
  34. Imai, S. -I., "Transcriptional silen cing and longevity protein Sir2 is an NAD-dependent histone deacetylase", Nature, 403, pp.795~800 (2000)
  35. Liu, T., "The critical role of the class III histone dea cetylase SIRT1 in cancer", Cancer Res, 69, pp.1702~1705 (2009)
  36. Raynes, R., "Stress inducibility of SIRT1 and its role in cytoprotection and cancer", Genes Cancer, 4, pp.172~182 (2013)
  37. Kaushal, P., "An SDS-PAGE based proteomic approach for N-terminome profiling", Analyst, 144, pp.7001~7009 (2019)
  38. Lee, S., "tipNrich : a tip-based N-terminal proteome enrichment method", Anal. Chem, 93, pp.14088~14098 (2021)
  39. Brademan, D. R., "Interactive peptide spectral annotator : a versatile web-based tool for proteomic applications", Mol. Cell. Proteom, 18, pp.S193~S201 (2019)
  40. Hussein, U. K., "Expression of oxidized protein tyrosine phosphatase and γH2AX predicts poor survival of gastric carcinoma patients", BMC Cancer, 18, pp.1~12 (2018)
  41. Park, H. J., "The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma", J. Exp. Clin. Cancer Res, 37, pp.1~15 (2018)
  42. Nusinow, D. P., "Quantitative proteomics of the cancer cell line encyclo pedia", Cell, 180, pp.387~402 (2020)
  43. Ghandi, M., "Next-generation characterization of the cancer cell line ency clopedia", Nature, 569, pp.503~508 (2019)
  44. Padovan, E., "Interferon stimulated gene 15 constitutively produced by melanoma cells induces E-cadherin expression on human dendritic cells", Cancer Res, 62, pp.3453~3458 (2002)
  45. Burks, J., "ISGylation governs the oncogenic function of Ki-Ras in breast cancer", Oncogene, 33, pp.794~803 (2014)
  46. Chen, Y. -L., "Interferon-stimulated gene 15 modulates cell migration by interacting with Rac1 and contributes to lymph node metastasis of oral squa mous cell carcinoma cells", Oncogene, 38, pp.4480~4495 (2019)
  47. Bektas, N., "The ubiquitin-like molecule interferon-stimulated gene 15(ISG15)is a potential prognostic marker in human breast cancer", Breast Cancer Res, 10, pp.1~12 (2008)
  48. Cruz, A. C. T., "Cell type-dependent regulation of free ISG15levels and ISGylation", J. Cell Commun. Signal, 11, pp.127~135 (2017)
  49. Chen, G., "Suppression of Sirt1 sensitizes lung cancer cells to WEE1 inhibitor MK-1775-induced DNA damage and apoptosis", Oncogene, 36, pp.6863~6872 (2017)
  50. Liu, M., "Camptothecin induces the ubiquitin like protein, ISG15, and enhances ISG15 conjugation in response to interferon", J. Interferon Cytokine Res, 24, pp.647~654 (2004)
  51. Zitvogel, L., "Type I interferons in anticancer immunity", Nat. Rev. Immunol, 15, pp.405~414 (2015)
  52. Benci, J. L., "Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade", Cell, 167, pp.1540~1554 (2016)
  53. Yeh, Y. -H., "A negative feedback of the HIF-1α pathway via interferon-stimulated gene 15 and ISGylation", Clin. Cancer Res, 19, pp.5927~5939 (2013)
  54. Levy, D. E., "Divergent roles of STAT1 and STAT5 in malignancy as revealed by gene disruptions in mice", Oncogene, 19, pp.2505~2510 (2000)
  55. Borden, E., "Comparative antiproliferative activity in vitro of natural interferons α and β for diploid and transformed human cells", Cancer Res, 42, pp.4948~4953 (1982)
  56. Weichselbaum, R. R., "An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer", Proc. Natl. Acad. Sci. USA, 105, pp.18490~18495 (2008)
  57. Erdal, E., "A prosurvival DNA damage-induced cytoplasmic interferon response is mediated by end resection factors and is limited by Trex1", Genes Dev, 31, pp.353~369 (2017)
  58. Jeon, Y. J., "ISG15 modification of filamin B negatively regulates the type I interferon-induced JNK signalling pathway", EMBO Rep, 10, pp.374~380 (2009)
  59. Im, E., "Covalent ISG15 conjugation positively regulates the ubiquitin E3 ligase activity of parkin", Open Biol, 6, pp.160193~ (2016)
  60. Kim, J. -E., "DBC1 is a negative regulator of SIRT1", Nature, 451, pp.583~ (2008)
  61. Zhao, W., "Negative regulation of the deacetylase SIRT1 by DBC1", Nature, 451, pp.587~ (2008)
  62. Kim, E. -J., "Active regulator of SIRT1 cooperates with SIRT1 and facilitates suppression of p53 activity", Mol. Cell, 28, pp.277~290 (2007)
  63. Dai, H., "Crystallographic structure of a small molecule SIRT1 activator enzyme complex", Nat. Commun, 6, pp.1~10 (2015)
  64. Jumper, J., "Highly accurate protein structure prediction with AlphaFold", Nature, 596, pp.583~589 (2021)
  65. Kang, H., "Peptide switch is essential for Sirt1 deacetylase activity", Mol. Cell, 44, pp.203~213 (2011)
  66. Patel, S. A., "Combination cancer therapy with immune checkpoint blockade : mechanisms and strategies", Immunity, 48, pp.417~433 (2018)
  67. Davenport, A. M., "Structural and functional analysis of human SIRT1", J. Mol. Biol, 426, pp.526~541 (2014)
  68. Dai Vu, L., "Protein language : post-translational mod ifications talking to each other", Trends Plant Sci, 23, pp.1068~1080 (2018)
  69. Leutert, M., "Decoding post-translational modification crosstalk with proteomics", Mol. Cell. Proteom, 20, pp.100129~ (2021)
  70. Lee, C. -W., "AMPK promotes p53 acetylation via phosphorylation and inactivation of SIRT1 in liver cancer cells", Cancer Res, 72, pp.4394~4404 (2012)
  71. Chattopadhyay, T., "Spatiotemporal gating of SIRT1 functions by O-GlcNAcylation is essential for liver metabolic switching and prevents hyper glycemia", Proc. Natl. Acad. Sci. USA, 117, pp.6890~6900 (2020)
  72. Zee, R. S., "Redox regulation of sirtuin-1 by S-glutathiolation", Antioxid. Redox Signal, 13, pp.1023~1032 (2010)
  73. Yang, Y., "SIRT1 sumoylation regulates its deacetylase activity and cellular response to genotoxic stress", Nat. Cell Biol, 9, pp.1253~1262 (2007)
  74. Wang, W., "JAK1-mediated Sirt1 phosphorylation functions as a negative feedback of the JAK1-STAT3 pathway", J. Biol. Chem, 293, pp.11067~11075 (2018)
  75. Lau, A. W., "SIRT1 phosphorylation by AMP-activated protein kinase regulates p53 acetylation", Am. J. Cancer Res, 4, pp.245~255 (2014)
  76. Gerhart-Hines, Z., "The cAMP", PKA pathway rapidly activates SIRT1 to pro mote fatty acid oxidation independently of changes in NAD+, 2011, pp.44, 851~863
  77. Kalous, K. S., "Human sirtuins are differentially sensitive to inhibition by nitrosating agents and other cysteine oxidants", J. Biol. Chem, 295, pp.8524~8536 (2020)
  78. Kalous, K. S., "Mechanism of Sirt1 NAD +-dependent protein deacetylase inhibition by cysteine S-nitrosation", J. Biol. Chem, 291, pp.25398~25410 (2016)
  79. Kornberg, M. D., "GAPDH mediates nitrosylation of nuclear proteins", Nat. Cell. Biol, 12, pp.1094~1100 (2010)
  80. Caito, S., "SIRT1 is a redox-sensitive deacetylase that is post-translationally modified by oxidants and carbonyl stress", Faseb J, 24, pp.3145~3159 (2010)
  81. Lin, Z., "USP22 antagonizes p53 transcriptional activation by deubiquiti nating Sirt1 to suppress cell apoptosis and is required for mouse embryonic development", Mol. Cell, 46, pp.484~494 (2012)
  82. Peng, L., "Ubiquitinated sirtuin 1(SIRT1)function is modulated during DNA damage-induced cell death and survival", J. Biol. Chem, 290, pp.8904~8912 (2015)
  83. Torre, L. A., "Lung cancer statistics", Lung Cancer Pers. Med, 893, pp.1~19 (2016)
  84. Chen, X., "Sirt1 is a tumor promoter in lung adenocarcinoma", Oncol. Lett, 8, pp.387~393 (2014)
  85. Grbesa, I., "Expression of sirtuin 1 and 2 is associated with poor prognosis in non-small cell lung cancer patients", PLoS One, 10, pp.e0124670~ (2015)
  86. Wang, J., "Prognostic and predictive role of Sirtuin1 expression in lung adenocarcinoma", Clin. Lab, 62, pp.1989~1994 (2016)
  87. Jin, X., "High expression of SIRT1 associates with the doxorubicin resistance of breast cancer through the activation of Akt", Anti Cancer Agents Med. Chem, 20, pp.94~102 (2020)
  88. Wei, T., "Magnoflorine improves sensitivity to doxor ubicin(DOX)of breast cancer cells via inducing apoptosis and autophagy through AKT", mTOR and p38 signaling pathways, 2020, pp.121, 109139~
  89. Xu, M., "CPEB1 mediates hepatocellular carcinoma cancer stemness and chemoresistance", Cell Death Dis, 9, pp.1~17 (2018)
  90. Chen, J., "Sirtuin 1 is upregulated in a subset of hepatocellular carcinomas where it is essential for telomere maintenance and tumor cell growth", Cancer Res, 71, pp.4138~4149 (2011)
  91. Song, S., "Protective effects of dioscin against doxorubicin-induced hepa totoxicity via regulation of Sirt1", FOXO1, Front. Pharmacol, pp.2019, 10[DOI]
  92. Villarroya-Beltri, C., "ISGylation controls exosome secretion by promoting lysosomal degradation of MVB proteins", Nat. Commun, 7, pp.1~11 (2016)
  93. Raso, M. C., "Interferon-stimulated gene 15 accelerates replication fork pro gression inducing chromosomal breakage", J. Cell Biol, 219, pp.e202002175~ (2020)
  94. Xu, D., "Modification of BECN1 by ISG15 plays a crucial role in autophagy regulation by type I IFN", interferon, 2015, pp.11, 617~628
  95. Kang, J. A., "Emerging roles of USP18 : from biology to pathophy siology", Int. J. Mol. Sci, 21, pp.6825~ (2020)
  96. Alcalá, S., "ISG15 and ISGylation is required for pancreatic cancer stem cell mitophagy and metabolic plasticity", Nat. Commun, 11, pp.1~17 (2020)
  97. Stark, G. R., "The JAK-STAT pathway at twenty", Immunity, 36, pp.503~514 (2012)
  98. Ummat, A., "Structural basis for cisplatin DNA damage tolerance by human polymerase η during cancer chemotherapy", Nat. Struct. Mol. Biol, 19, pp.628~632 (2012)
  99. Wang, B., "NBA1, a new player in the Brca1A complex, is required for DNA damage resistance and checkpoint control", Genes Dev, 23, pp.729~739 (2009)
  100. Wood, L. M., "The ubiquitin-like protein, ISG15, is a novel tumor-associated antigen for cancer immunotherapy", Cancer Immunol. Immunother, 61, pp.689~700 (2012)

이 간행물의 다른 논문 (218건)

Big data and deep learning for RNA biologyJeon Hyeonseong, Baek Daehyun, Hwang Hyeonseo, Yeo Nagyeongpp. 1-29RGS19 activates the MYH9/β-catenin/c-Myc positive feedback loop in hepatocellular carcinomaXu Yanan, Ke Shanjia, Lu Shounan, Bai Miaoyu, Yu Hongjun, Yin Bing, Wang Chaoqun, Feng Zhigang, Li Zihao, Huang Jingjing, Li Xinglong, Qian Baolin, Hua Yongliang, Fu Yao, Sun Bei, Wu Yaohua, Ma Yongpp. 1-14Molecular mechanisms of circular RNA translationKim Yoon Ki, Hwang Hyun Jungpp. 1-9The m6A writer RBM15 drives the growth of triple-negative breast cancer cells through the stimulation of serine and glycine metabolismKim Ho, Yun Hye Jin, 이종호, Lee Su Bin, Kim Seok-Ho, Park Yun-Yong, Park Su Hwan, Ju Jin-Sung, Woo Hyunmin, Győrffy Balázs, Kim Eun-jeong, Han Hee Dong, Eyun Seong-ilpp. 1-15Neuron type-specific optogenetic stimulation for differential stroke recovery in chronic capsular infarctKim Ra Gyung, Cho Jongwook, Park Ji-Young, Kim Young Ro, Lee Min-Cheol, Kim Hyoung-Ihlpp. 1-11
원문 보기